The VADEX technology platform is a self-adjuvanting protein nanoparticle platform. Its constituent units are formed by fusing a specific-sequence amphiphilic peptide with a superfolder green fluorescent protein. Although this amphiphilic peptide is only 19 amino acids long, it possesses both adjuvant functionality and nanoparticle self-assembly capability. Foreign proteins can be directly fused onto the nanoparticles or linked to the nanoparticles through irreversible complementary conjugation. Because nanoparticles formed using VADEX technology can induce long-lasting antibody responses without the need for external adjuvants, vaccines developed based on VADEX technology can withstand high temperatures of up to 40°C for more than two months. With this technology, children around the world, whether living in deserts or tropical rainforests, will be able to grow up healthy in the future.

1. T-1101: Global first-in-class Hec1/Nek2 targeted small molecule inhibitor
2. T-1201: Novel targeted small molecule-SN-38 conjugate anticancer drug
3. T-1301: Multi-targeted tyrosine kinase inhibitor
4. T-1501: Novel small molecule-DM-1 conjugate targeted anticancer drug

Neurology
Pipeline
Utilizing Yoda’s proprietary AI-based drug screening platform, we engage in the exploration and development of promising and beneficial products to address unmet medical needs, instilling new hope in patients.YA-101 Multiple System Atro

Integrated AI Drug Discovery Platform: An AI-driven multi-model platform that accelerates drug repurposing by integrating diverse data types, multiple R&D methodologies, various analytical modalities, and a wide range of AI algorithms.